107 days ago
Yes, I still think that shares in Skinbiotherapeutics (SBTX) are cheap at 19p, that there will be three quarters of revenues from Croda booked in the year to June 30 2025 with two quarters fully paid. But I see that the shares are off a penny today because we know what is looming.
118 days ago
I am not normally one to praise Stuart Ashman the CEO and Manprick the grossly overpaid CFO at Skinbiotherapeutics (SBTX) but yesterday’s investor meet presentation and Q&A was a very good showing by them both, especially Ashman. There I have said it. My key takeaways are:
443 days ago
It was an hour of my time which I may look back on my deathbed and consider an hour wasted. I should say that, on balance, there was enough offered by Ashman to make me content to hold shares in Skinbiotherapeutics (SBTX) but there were also worrying matters not least the CEO telling a blatant lie.
